(AOF) – Genomic Vision, a biotech specialist in the precise characterization of DNA sequences, presented its new strategic orientation. It will work to advance genomic analysis in “biomanufacturing, cell and gene therapies and drug discovery”, but also “innovation for quality control throughout the biomanufacturing cycle”. The company will launch AI-based analysis software and a technology platform to accelerate and simplify high-throughput genomic analysis.
Genomic Vision says this strategy of coupling AI and genomics, supported by strategic partnerships, puts it “at the forefront of the genomics industry”, a global market that is expected to reach $62.9 billion. by 2028. Its ambition is to be “one of the precursors of this high-growth industry”. The market addressable by Genomic Vision’s technology and its associated services is estimated at $4.8 billion, with average double-digit annual growth.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.